Table 2.
Clinical backgrounds by different NUCs treatment (n=142)
| LAM and/or ETV | ADV or TDF | p Value | |
|---|---|---|---|
| N | 117 | 25 | |
| Age (years)* | 59 (31–86) | 62 (37–80) | NS |
| Sex (M:F) | 78:39 | 14:11 | NS |
| HBV genotype (A:B:C:D:ND) |
2:15:92:0:8 | 0:2:21:0:2 | NS |
| Alb (g/dL)* | 4.4 (2.1–5.1) | 4.4 (3.3–5.3) | NS |
| AST (U/L)* | 22 (13–238) | 21 (16–45) | NS |
| ALT (U/L)* | 19 (8–373) | 18 (8–54) | NS |
| ChE (U/L)* | 296 (38–578) | 279 (151–443) | NS |
| T-cho (mg/dL)* | 179 (85–315) | 158 (113–226) | NS |
| BUN (mg/dL)* | 14 (6–39) | 17 (1–25) | NS |
| Cre (mg/dL)* | 0.77 (0.37–2.41) | 0.79 (0.47–1.99) | NS |
| Plt (×104/μL)* | 15.6 (2.5–26.3) | 16.4 (8.1–28.7) | NS |
| AFP (ng/mL)* | 2.5 (0.8–4834) | 2.1 (0.8–5.6) | NS |
| HBsAg (IU/mL)* | 826 (1–47 205) | 464 (1–8150) | NS |
| HBeAg+† | 34 (29.1%) | 5 (20.0%) | NS |
| HBV DNA (log copies/mL)* | UD (UD–8.4) | UD (UD–3.7) | NS |
| IL-28B (TT:non-TT) | 90:27 | 15:10 | NS |
| CH:LC | 72:45 | 17:8 | NS |
| HCC† | 34 (29.1%) | 6 (24.0%) | NS |
| Duration of NUC treatment* (months) |
37 (1–135) | 92 (17–148) | <0.001 |
| Serum IFN-λ3 (pg/mL)* | 1.4 (0.1–32.5) | 27.2 (3.4–113.2) | <0.001 |
*Data are presented as the median (range).
†Data are presented as a positive number (%).
ADV, adefovir pivoxil; AFP, α-fetoprotein; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CH, chronic hepatitis; ChE, cholinesterase; Cre, creatine; ETV, entecavir; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; IFN, interferon; IL-28B, interleukin 28B; LAM, lamivudine; LC, liver cirrhosis; ND, not determined; NS, non-significant; NUC, nucleos(t)ide analogue; Plt, platelet count; T-cho, total cholesterol; TDF, tenofovir disoproxil fumarate; TT, major homozygous genotype of IL-28B; UD, under detection threshold.